Synthetic porous crystalline material ITQ-12, its synthesis and use

Details for Australian Patent Application No. 2002303663 (hide)

Owner ExxonMobil Research and Engineering Company

Inventors Camblor, Miguel A; Boix, Teresa; Corma, Avelino; Puche, Marta

Agent Watermark

Pub. Number AU-B-2002303663

PCT Number PCT/US02/14410

PCT Pub. Number WO2002/096802

Priority 09/866,903 29.05.01 US

Filing date 7 May 2002

Wipo publication date 9 December 2002

Acceptance publication date 29 March 2007

International Classifications

C01B 37/02 (2006.01) Compounds characterised primarily by their physical or chemical properties, rather than by their chemical constitution

C01B 39/12 (2006.01) Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites

C01B 39/48 (2006.01) Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites

C07C 1/24 (2006.01) Hydrocarbons

Event Publications

12 December 2002 Complete Application Filed

  Priority application(s): 09/866,903 29.05.01 US

8 May 2003 Application Open to Public Inspection

  Published as AU-B-2002303663

29 March 2007 Application Accepted

  Published as AU-B-2002303663

2 August 2007 Standard Patent Sealed

3 December 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2002303664-SULFONAMIDES

2002303662-HYALURONIC ACID CONTAINING BIOCONJUGATES : TARGETED DELIVERY OF ANTI-CANCER DRUGS TO CANCER CELLS